Abstract 12627: First-Generation Drug-Eluting Stent Versus Everolimus-Eluting Stents to Coronary Intervention in Dialysis Patients
Background: The restenosis rate of the follow-up period after percutaneous coronary intervention (PCI) has been yet high in patients on maintenance hemodialysis (HD) even if treated with sirolimus-eluting stent (SES). Recently, everolimus-eluting stent (EES) has been widely used in PCI procedure. However, until now, there are limited data concerning the effects of EES in HD patients undergoing PCI. The aim of this study was to compare the effects of SES and EES in preventing restenosis in HD patients with coronary artery disease.
Methods: A total of 100 consecutive patients on HD who underwent PCI were enrolled into the study. They were randomly assigned to receive SES or EES. The primary endpoint of the study was to compare angiographic outcomes between the SES and EES groups at 8 month after PCI.
Results: There were no differences between the two groups in baseline patients and lesion characteristics. Angiographical data were also similar between the two groups before and after PCI. The angiographical restenosis rate defined as % diameter stenosis > 50% by quantitative coronary angiography was 21.2% in the SES group and 8.7% in the EES group at 8-month follow-up (p = 0.041). Significant differences between the two groups were seen in % diameter stenosis (%DS), minimal lumen diameter, and late lumen loss at 8-month follow-up (24.1 ± 23.0 % vs. 12.0 ± 21.9%, p = 0.0024, 2.14 ± 0.74 mm vs. 2.48 ± 0.59mm, p = 0.0040, and 0.53 ± 0.71 mm vs. 0.26 ± 0.73mm, p = 0.033, respectively) (Table). Even after adjustment for other risk factors, EES implantation was an independent predictor for reduction of restenosis (Odds ratio 0.20, 95% confidential interval 0.05-0.78, p = 0.022).
Conclusions: HD patients treated with EES had significantly improved event-free survival rate from restenosis at 8-month follow-up compared to those with SES.
- © 2011 by American Heart Association, Inc.